drugset / Trial / NCT00937183
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Biological therapies, such as a dendritic cell vaccine made with a patient's cancer cells, may stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This phase I/II trial is studying the side effects of dendritic cell vaccine and to see how well it works in treating patients with indolent B-cell lymphoma or multiple myeloma.
Timeline
- Start
- 2003-09
- Primary completion
- 2017-06
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine | Vaccine | — | Subcutaneous |
| Subject | autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine | Vaccine | — | Subcutaneous |
| Subject | autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine | Vaccine | — | Subcutaneous |